Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy
More than 100 drugs have been approved to treat cancer, but predicting which ones will help a particular patient is an inexact science at best.
A new device developed at MIT may change that. The implantable device, about the size of the grain of rice, can carry small doses of up to 30 different drugs. After implanting it in a tumor and letting the drugs diffuse into the tissue, researchers can measure how effectively each one kills the patient’s cancer cells.
Such a device could eliminate much of the guesswork now involved in choosing cancer treatments, says Oliver Jonas, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and lead author of a paper describing the device in the April 22 online edition of Science Translational Medicine.
“You can use it to test a patient for a range of available drugs, and pick the one that works best,” Jonas says.
The paper’s senior authors are Robert Langer, the David H. Koch Professor at MIT and a member of the Koch Institute, the Institute for Medical Engineering and Science, and the Department of Chemical Engineering; and Michael Cima, the David H. Koch Professor of Engineering at MIT and a member of the Koch Institute and the Department of Materials Science and Engineering.
Putting the lab in the patient
Most of the commonly used cancer drugs work by damaging DNA or otherwise interfering with cell function. Recently, scientists have also developed more targeted drugs designed to kill tumor cells that carry a specific genetic mutation. However, it is usually difficult to predict whether a particular drug will be effective in an individual patient.
In some cases, doctors extract tumor cells, grow them in a lab dish, and treat them with different drugs to see which ones are most effective. However, this process removes the cells from their natural environment, which can play an important role in how a tumor responds to drug treatment, Jonas says.
“The approach that we thought would be good to try is to essentially put the lab into the patient,” he says. “It’s safe and you can do all of your sensitivity testing in the native microenvironment.”
The device, made from a stiff, crystalline polymer, can be implanted in a patient’s tumor using a biopsy needle. After implantation, drugs seep 200 to 300 microns into the tumor, but do not overlap with each other. Any type of drug can go into the reservoir, and the researchers can formulate the drugs so that the doses that reach the cancer cells are similar to what they would receive if the drug were given by typical delivery methods such as intravenous injection.
After one day of drug exposure, the implant is removed, along with a small sample of the tumor tissue surrounding it, and the researchers analyze the drug effects by slicing up the tissue sample and staining it with antibodies that can detect markers of cell death or proliferation.
Ranking cancer drugs
To test the device, the researchers implanted it in mice that had been grafted with human prostate, breast, and melanoma tumors. These tumors are known to have varying sensitivity to different cancer drugs, and the MIT team’s results corresponded to those previously seen differences.
The researchers then tested the device with a type of breast cancer known as triple negative, which lacks the three most common breast cancer markers: estrogen receptor, progesterone receptor, and Her2. This form of cancer is particularly aggressive, and none of the drugs used against it are targeted to a specific genetic marker.
Using the device, the researchers found that triple negative tumors responded differently to five of the drugs commonly used to treat them. The most effective was paclitaxel, followed by doxorubicin, cisplatin, gemcitabine, and lapatinib. They found the same results when delivering these drugs by intravenous injection, suggesting that the device is an accurate predictor of drug sensitivity.
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Carlsmed raises $2.5M to create personalized implants for spinal surgeryon June 24, 2020 at 5:48 pm
The current standard of care is to use predefined sizes and configurations of implants to correct the spine through a trial and error method during surgery. This leads to extended surgery times and ...
- MindMed Developing IP For Personalized Psychedelic Assisted Therapieson June 23, 2020 at 9:05 pm
PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, ...
- Johns Hopkins Leverages Microsoft AI for Precision Medicineon June 22, 2020 at 6:56 am
Johns Hopkins Medicine will leverage Microsoft Azure's artificial intelligence and analytics tools to advance precision medicine discoveries.
- Why Personalized Medicine Has The Power And Potential To Extend Your Lifeon June 22, 2020 at 4:34 am
Due to advancements in AI and wearables, quicker and better diagnoses, effective and personalized treatment, and unprecedented technological advancements, humans may be able to live past 100 in the ...
- Personalized Medicine Market 2020 Worldwide Opportunities, Driving Forces, COVID-19 Impact Analysis, Future Potential 2028on June 21, 2020 at 11:05 pm
What is Personalized Medicine Market?Advancements in science and technology are fluctuating, especially the way we ...
- Assessment of COVID-19's Effect on Breast Cancer Liquid Biopsy Testing Devices Market 2020-2024 | Enhanced Emphasis on Personalized Medicine to Augment Growth | Technavioon June 19, 2020 at 11:00 am
Technavio has announced its latest market research report titled Global Breast Cancer Liquid Biopsy Testing Devices Market 2020-2024 (Graphic: Business Wire) LONDON-- ( BUSINESS WIRE )--Technavio has ...
- Personalized Meds Will Drive Sector-Wide Bioprocessing Innovationon June 16, 2020 at 12:00 pm
Precision medicine is extremely disruptive to the model of a blockbuster molecule produced in centralized facilities so that flexible tech and non-traditional sites will play a greater role.
- Global Personalized Medicine Market 2020-2025 - Current Technologies Propelling Market Growthon June 15, 2020 at 11:45 am
The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2025 - Strategic Analysis of Industry ...
- Personalized Medicine Market Size Per Country (The Top 10 Markets), Market Analysis, Key Players, Target Audience and Forecast to 2027on June 12, 2020 at 6:03 am
As per the research held by Acumen Research and Consulting, The global Personalized Medicine Market is expected to reach a value of around US$ 1.7 Trillion by 2027 and expanding at a CAGR of 9.1% from ...
- Global Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market Analysis and Forecasts to 2025 - ResearchAndMarkets.comon June 10, 2020 at 2:30 am
The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2025 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report has been added to ...
via Bing News